TITLE

NSAIDs: the Emperor's new dogma?

AUTHOR(S)
Bjarnason I; Takeuchi K; Simpson R
PUB. DATE
September 2003
SOURCE
Gut;Sep2003, Vol. 52 Issue 9, p1376
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The spectacular marketing success of the selective cyclooxygenase 2 (COX-2) inhibitors is largely based on efficacy comparable with conventional non-steroidal anti-inflammatory drugs (NSAIDs) with vastly improved gastrointestinal safety. The additional key to the marketing success is the purity and simplicity of the message-that is, COX-1 inhibition causes the gastrointestinal side effects of NSAIDs (COX-1 dogma) while COX-2 blocking confers the therapeutic benefits (COX-2 dogma). Adherence to the COX dogmas with development of COX-2 selective agents has undoubtedly benefited many patients, but ironically their scientific basis is now seriously challenged by experimentation.
ACCESSION #
10631327

 

Related Articles

  • What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). Wooltorton, Eric // CMAJ: Canadian Medical Association Journal;6/25/2002, Vol. 166 Issue 13, p1692 

    Discusses the use of non-steroidal anti-inflammatory agents (NSAID), which have been associated with gastrointestinal events. Safety concerns about selective cyclooxygenase-2 (COX-2) inhibitors such as rofecoxib (Vioxx) and celecoxib (Celebrex), which were developed as an alternative to NSAID;...

  • Study evaluates aspirin comedication rates among long-term COX-2 inhibitor users.  // Formulary;Sep2004, Vol. 39 Issue 9, p434 

    Evaluates aspirin comedication rates among long-term COX-2 inhibitor users. Lack of difference in gastrointestinal infection ulcer complication rates between celecoxib and nonselective NSAID; Percentage of comedication with over-the-counter pain relievers.

  • Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003? Yuan, Yuhong; Hunt, Richard H. // Inflammopharmacology;2003, Vol. 11 Issue 4-6, p337 

    Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely used drugs worldwide despite their well-documented adverse gastrointestinal (GI) effects. The risk of developing a severe GI event varies from patient to patient and NSAID to NSAID. Selective cyclo-oxygenase-2 inhibitors...

  • COX-2 Inhibitors – Lessons in Drug Safety. Psaty, Bruce M.; Furberg, Curt D. // New England Journal of Medicine;3/17/2005, Vol. 352 Issue 11, p1133 

    The article focuses on the authors' views on the use of cyclooxygenase-2 (COX-2) inhibitors. The authors say that COX-2 inhibitors, which were meant to deflect the gastrointestinal complications common to other nonsteroidal anti-inflammatory drugs, have shown serious adverse cardiovascular...

  • What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). Wooltorton, Eric // CMAJ: Canadian Medical Association Journal;6/25/2002, Vol. 166 Issue 13, p1692 

    Discusses the use of non-steroidal anti-inflammatory agents (NSAID), which have been associated with gastrointestinal events. Safety concerns about selective cyclooxygenase-2 (COX-2) inhibitors such as rofecoxib (Vioxx) and celecoxib (Celebrex), which were developed as an alternative to NSAID;...

  • A COX-2-Specific Inhibitor Plus a Proton-Pump Inhibitor: Is This a Reasonable Approach to Reduction in NSAIDs' GI Toxicity? Cryer, Byron // American Journal of Gastroenterology;Apr2006, Vol. 101 Issue 4, p711 

    The two prevailing approaches to decrease risks of nonsteroidal anti-inflammatory drug (NSAID)-associated gastrointestinal (GI) events are the use of a COX-2 inhibitor or co-therapy with a proton-pump inhibitor (PPI). A major limitation of each approach is that, in patients at the highest risk...

  • Appropriate use of NSAIDs. Stillman, Martin J.; Stillman, M. Thomas // Geriatrics;Mar2007, Vol. 62 Issue 3, p16 

    In the first of this two-part article, we reviewed essential gastrointestinal (GI) data necessary for choosing selective COX-2 inhibitors (coxibs) versus nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), as well as other NSAID-related GI issues. Although GI considerations are critical...

  • COX-2 inhibitors: a story of greed, deception and death. Halpern, Georges M. // Inflammopharmacology;2005, Vol. 13 Issue 4, p419 

    In 1999, drug manufacturers introduced a class of NSAIDs called COX-2 inhibitors or coxibs. The drugs were avidly promoted directly to the consumers and became bestsellers from the start. Arthritis sufferers were eager to take medications that eased joint pain with less risk of causing...

  • Editorial [Hot Topic: Anti-Inflammatory Therapy (Guest Editor: Dr. Subhash P. Khanapure)]. Khanapure, Subhash P. // Current Topics in Medicinal Chemistry;Feb2007, Vol. 7 Issue 3, p233 

    Significant advances for treating the signs and symptoms of inflammatory disease have been made in the last decade. Most of the existing anti-inflammatory drugs are effective, but not without adverse effects. Various strategies have been employed to overcome the major problem of the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics